The Daily Biotech Pulse: Europe Approves Second Round Of Booster Doses of mRNA COVID-19 Vaccines, Perrigo Seeks Approval For First OTC Birth Control Pill, MacroGenics Closes Head & Cancer Study After Patient Death

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus European Regulator Recommend Additional Booster Doses of mRNA COVID-19 Vaccines The European Centre for Disease Prevention & Control and the European Medicines Agency have recommended second booster doses  of mRNA COVID-19 vaccines for people between 60 and 79. In April 2022, the agencies recommended that people over 80 be considered for a second booster. The move comes after a new wave is underway in Europe, with increasing hospital and intensive care unit rates. Perrigo Files US Application For First OTC Birth Control Pill Perrigo Company plc's  (NYSE: PRGO ) HRA Pharma has submitted its application to the FDA  for the first-ever over-the-counter (OTC) birth control pill. The company has applied for an Rx-to-OTC switch for Opill, a progestin-only daily birth control pill (also referred to as a mini pill or non-estrogen pill). Shares are up 2.31% at $42.05 during the premarket session. Ionis Partner Licenses Rare Kidney Disease Treatment Ionis Pharmaceuticals Inc  (NASDAQ: IONS ) said that its long-standing partner, Roche Holdings AG  (OTC: RHHBY ), will license and advance  IONIS-FB-LRx, an investigational antisense medicine, into a Phase 3 study immunoglobulin A nephropathy.  Roche's decision to advance the program comes after positive data from a Phase 2 ... Full story available on Benzinga.com